Dotmatics

Lessons Learned for AI in Small Molecule Drug Discovery

The webinar titled "Lessons Learned for AI in Small Molecule Drug Discovery," held online on December 6th, 2022, discusses the longstanding but recently hyped use of AI and machine learning in drug discovery, emphasizing the need to adjust expectations, drawing lessons from past technology challenges and other industries, and outlining three key factors for successful AI implementation in the field.

Online

Lessons Learned for AI in Small Molecule Drug Discovery

December 6th, 2022

14:20 GMT

Online

Despite the buzz around artificial intelligence (AI), most industry insiders know that the use of machine learning (ML) in drug discovery is nothing new. For more than a decade, researchers have used computational techniques for many purposes, such as finding hits, modeling drug-protein interactions, and predicting reaction rates.

What is new is the hype. As AI has taken off in other industries, countless start-ups have emerged promising to transform drug discovery and design with AI-based technologies. While a few “AI-native” candidates are in clinical trials, around 90% remain in discovery or preclinical development, so it will take years to see if the bets pay off. This begs the question: Is AI for drug discovery more hype than hope? Absolutely not. Do we need to adjust our expectations and position for success? Absolutely, yes.

In this webinar, we will discuss:

  • Learnings form previous technology implementation challenges and

  • Learnings from adjacent industries.

  • Three Keys to Successful AI implementation